Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:23:11.253Z.
Calculation as of: 2026-10-06T17:23:11.253Z.
Quote observation: 2026-10-06T17:19:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fd4e67db9f72c8f7e350226876d0b852307266b6ff0bede5899e1be1bde0c950
PE RATIO
N/A
Polaryx Therapeutics, Inc. Common Stock
Market Cap
$105.67M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.28M
PE Ratio
N/A
TTM Avg
597.78
3Y Avg
597.78
5Y Avg
597.78
Market Cap
$106.69M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.15M
PE Ratio
N/A
TTM Avg
17.69
3Y Avg
17.69
5Y Avg
17.69
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $105.67M | N/A | N/A | N/A | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.28M | N/A | 597.78 | 597.78 | 597.78 |
| Definitive Healthcare Corp. (DH)vs › | $105.22M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $106.04M | N/A | N/A | N/A | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $101.24M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $106.69M | N/A | N/A | N/A | N/A |
| The Joint Corp. (JYNT)vs › | $102.61M | 27.15 | 39.41 | 48.57 | 115.64 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.15M | N/A | 17.69 | 17.69 | 17.69 |
| Outlook Therapeutics, Inc. (OTLK)vs › | $108.05M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $108.78M | N/A | 2144.18 | 993.27 | 551.35 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.12
Forward EPS (Est.)
$-0.19
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
